Objectives: Pharmacogenomic applications in oncology offer significant promise, but the clinical and economic implications remain unclear. The objective of this study was to evaluate the potential cost-utility of implementing epidermal growth factor receptor (EGFR) testing before initiating second-line therapy for advanced refractory non-small-cell lung cancer (NSCLC).
Increased understanding of the molecular mechanisms of cancer has enhanced our ability to estimate the risk of cancer development and relapse [1, 2] , develop new therapeutics [3] [4] [5] [6] , and target therapy according to the unique molecular characteristics of tumor tissue [7] [8] [9] [10] -innovations that generally fall under the developing field of pharmacogenomics. Relative to other disease areas, a larger number of pharmacogenomic applications in or near clinical use are available in oncology, including HER2 testing with Herceptin, the OncotypeDx assay in breast cancer, UGT1A1 testing with irinotecan in colon cancer, and TPMT testing with 6-mercaptopurine in acute lymphoblastic leukemia, among others [7] [8] [9] [10] . In addition, recent studies have indicated that pharmacogenomics may play a significant role in second-line non-small-cell lung cancer (NSCLC) treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) [11] [12] [13] [14] [15] [16] [17] .
The epidermal growth factor receptor is a cell membrane protein involved in cellular signaling and the downstream processes of apoptosis, cell growth, and cellular differentiation among others [18] . As such, the EGFR gene is considered a proto-oncogene or one that could, if altered in its activity or expression, produce malignancy [19] . It is overexpressed in many solid tumors including gliomas, breast, colon, and NSCLC, which led to its candidacy for inhibitor therapy and the development of EGFR-targeted agents [18] . The importance of EGFR in NSCLC is supported by the successful clinical trials for erlotinib (ERL) (BR. 21) , which demonstrated better survival compared to best supportive care (BSC) [3] . Nevertheless, EGFRtargeted agents have relatively low response rates (~10-20%), suggesting the potential for a biologically identifiable subset of responder patients [3, 20] . In the BR.21 trial, prespecified subgroup analyses showed better response and survival for ERL compared to BSC (hazard ratio [HR] 0.68, 95% CI 0.49-0.95) in patients who tested positive for high EGFR protein expression using immunohistochemical (IHC) testing-a method for evaluating the amount of EGFR protein in tumor tissue, whereas no survival benefit was shown for those testing negative (HR 0.93, 95% CI 0.63-1.36) [12, 21] . A similar pattern was found for patients with high (HR 0.44, 95% CI 0.23-0.82) and low (HR 0.85, 95% CI 0.48-1.51) EGFR gene copy number evaluated using fluorescent in situ hybridization-a measure of the number of copies of the EGFR gene in tumor cells [12] [13] [14] [15] [16] [17] . These analyses were retrospective and limited by sample availability with approximately 33% and 17% of patients able to be evaluated by IHC and gene copy number testing (GC), respectively [12] . To date, there have been no clinical trials comparing EGFR testing versus standard care.
In the absence of direct comparisons in clinical trials, we have undertaken an indirect comparison to estimate the cost-utility of EGFR testing in second-line NSCLC using the exploratory data generated in the BR.21 trial. The objective of this study was to evaluate the likely clinical and economic impact of implementing an EGFR testing strategy versus standard care (no testing). This case is particularly salient as there are a number of drugs developed or in development targeting EGFR and both gene copy number and protein expression tests have been proposed as useful tools for selecting patients for EGFR-TKI therapy [13, 20, [22] [23] [24] [25] . Despite the enthusiasm, these clinically available tests are not commonly used in practice, which is likely attributable to the exploratory nature of the current evidence in favor of testing. Clearly, more effective interventions in lung cancer treatment are needed because of the high burden of illness (213,000 new cases and 160,000 deaths expected in 2007 in the USA) and associated economic burden (approximately $5 billion dollars per year in the USA) [26, 27] . The results of this analysis will inform the ongoing debate and research agenda for EGFR pharmacogenomic testing in advanced refractory NSCLC.
Research Design and Methods
We developed a decision analytic model using partition survival methods, in which the overall effectiveness of the interventions was derived by summing the mean time spent in the progressionfree and disease progression (PD) health states adjusted for quality of life, to assess the quality-adjusted life years (QALYs) and associated costs of using a pharmacogenomic testing treatment approach in second-line NSCLC. The model consisted of a decision tree ( Fig. 1 ) in which patients received ERL monotherapy or one of two EGFR testing strategies: EGFR protein expression test (EGFR PharmDx kit, DakoCytomation, Glostrup, Denmark), with ERL given to patients with high expression (greater than 10% of cells staining) and docetaxel for those with low expression (IHC); or an EGFR gene copy number test using fluorescent in-situ hybridization with ERL given to patients with high copy number according to commonly used criteria and docetaxel given to those with low copy number [12, 17, 28] . After treatment assignment, patients could remain progression-free or experience PD until death and were followed for time in the progression-free state, time in PD, quality of life, and costs.
The study population consisted of advanced (stage IIIB/IV) NSCLC patients 60 years old (approximate median age in the pivotal trials for the therapies under investigation) who failed at least one platinum-based chemotherapy regimen and were eligible for treatment with ERL or other chemotherapy in the second-line setting [3, 29, 30] . The second-line setting was appropriate for comparison because there are three commonly used therapeutic agents approved by the Food and Drug Administration for treatment of NSCLC patients who fail to respond or progress after initial chemotherapy [3, 29, 30] . Although the optimal treatment strategy remains uncertain given the lack of direct comparisons between ERL and either docetaxel or pemetrexed, ERL was chosen as the no test comparator because its efficacy may be influenced by a patient's EGFR status. Therefore, the relevant policy question concerns whether clinicians favoring the use of ERL should employ an EGFR test before treatment Figure 1 Decision tree.The schema above illustrates the decision model used in our analysis. Patients entered the model and received an EGFR gene copy number or protein expression test or standard care with erlotinib.They were followed for time in the progression-free and disease progression health states, adverse events, and direct medical costs. EGFR, epidermal growth factor receptor; NSCLC, nonsmall cell lung cancer.
initiation to select an alternative treatment for patients unlikely to benefit from ERL. In addition, ERL has demonstrated a similar survival benefit to both docetaxel and pemetrexed (approximate 2-month survival benefit over BSC) with better tolerability and ease of administration [31] . We chose docetaxel for use in test-negatives as it is the most commonly prescribed chemotherapy agent used in second-line NSCLC and demonstrated similar survival to pemetrexed in a head to head trial [29, 32] . Patients who fail after second-line treatment were assumed to receive palliative care until death.
We performed a cost-utility analysis and followed the guidance of the US Panel on Cost-Effectiveness in Health and Medicine [33] . The analysis was conducted from the US societal perspective with a time horizon of 2 years in the base case (2-year survival rates in second-line NSCLC: ERL:~1%, docetaxel: 0%) [3, 29] . Costs and outcomes beyond 1 year were discounted at 3% in the base case [33] .
Clinical Inputs
We used estimates of overall survival (OS), from which times in progression-free survival (PFS) and time in progressive disease were derived, based on published randomized controlled trials. Four pivotal trials, comprising the best evidence to date, were used to evaluate the efficacy of the treatments investigated in this model [3, 29, 30, 34] . ERL and docetaxel appear to have similar survival benefits over BSC (approximately 2 months) in unselected advanced refractory NSCLC populations [3, 29, 30, 34] . We therefore assumed that the OS benefit for docetaxel was equal to ERL in NSCLC populations of mixed EGFR genomic status-an assumption used in previous economic evaluations of these treatments [35, 36] . Survival estimates for these treatments were based on the ERL manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) in the UK and a reanalysis of the BR.21 trial data by Pompen et al. (Table 1 ) [35, 37] .
The survival estimates for the testing arms were calculated as the average of the survival of the test-positive group (by either gene copy number or protein expression) which received ERL and the test-negative group which received docetaxel, weighted by the estimated prevalence of the testing groups [13, [38] [39] [40] . We adjusted our estimates to account for differences between the subgroup with test results available and the entire study population, while maintaining the between genomic group prognostic relationship (i.e., the relationship between untreated groups) as well as the within genomic group treatment effect (i.e., the relationship between the untreated and treated groups within a genomic subgroup), using the following equations:
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Where + orindicates marker positive or negative; all = all study patients; tested = study patients for whom there are test results; Tx = treated group; BSC = best supportive care/untreated group; TE = treatment effect; a = adjusted; and i = unadjusted (e.g., OS all BSC = the estimate for the OS in the untreated group from the entire study population).
Ideally, we would have marker status data for all study participants. Nevertheless, using this adjustment, the weighted average of our survival inputs in the genomic subgroups was equal to those in the overall study population allowing for comparability between our intervention arms.
The treatment benefit of docetaxel was applied to the adjusted untreated survival estimate from Equation 2 to obtain the overall treated survival estimate in the test-negative group, with the assumption that EGFR status does not affect the treatment benefit of docetaxel [41, 42] . Times in PFS and PD were derived by assuming the same ratio of PFS or PD to OS as seen in the overall study population.
Utilities were derived from two recent community-based studies in advanced NSCLC from the UK, which used the standard gamble interview and visual analog scale to assess quality of life (see Table 1 ) [43] [44] [45] . The disutility for adverse events (AEs) was applied to the first month of therapy as the majority of AEs occur in first month and would not be expected to last longer than 1 month.
Adverse event rates were estimated from published clinical trial data and drug package inserts. AEs included were grade 3/4 events greater than 5% or those requiring hospitalization for either medication. These AEs were chosen as they represent those likely to impact quality of life and for which direct health-care costs will accrue.
Resource Utilization and Unit Costs
Drug utilization rates were estimated from the published randomized controlled trials. For ERL, we used mean treatment duration (4.11 months) and assumed a course of treatment of 150 mg once daily by mouth and adjusted for potential wastage (5.1%) and dose intensity [35, 45, 46] . Drug utilization for patients testing positive was derived by adjusting the treatment duration in the overall population by the ratio of PFS estimates. The drug utilization for docetaxel in test-negatives was estimated using the mean number of cycles from the TAX 317 trial (4.82 cycles) for the 75 mg/m 2 group [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . We used the dosing scale for docetaxel (75 mg/m 2 ) from the key pivotal trials (mean BSA of 1.8 m 2 ) and adjusted for dose intensity received [3, 10, 29, 48, 49] .
For the drugs evaluated, we used the wholesale acquisition costs for 2006 [31] . The unit costs for medical services were estimated from the Centers for Medicare & Medicaid Services (CMS) physicians fee schedule and acute inpatient prospective payment system [50] . Drug administration costs for docetaxel included one outpatient office visit and 1 hour of intravenous (IV) infusion time per cycle. Drug administration costs for ERL included one outpatient office visit for the first prescription.
Testing costs were estimated using the current procedural terminology (CPT) codes associated with gene copy number tests (CPT code: 88368x2) and the PharmDx EGFR protein expression test (CPT code: 88342) [50] . Additional diagnostics in the model included routine blood work, chest x-rays, and computerized tomography scans associated with treatment and patient evaluation.
The cost of febrile neutropenia included hospitalization for neutropenia (diagnosis-related group [DRG] 398) and one inpatient physician visit. The cost of nonfebrile neutropenia included one additional outpatient office visit. We assumed a proportion of neutropenic patients received granulocyte colony stimulating factor for initial treatment and as prophylaxis for subsequent treatment cycles based on observed rates (docetaxel: 19.2%) [29, 51] .
Treatment for severe anemia included one additional outpatient office visit. In addition, a proportion of anemic patients were assumed to receive erythropoietin (one vial per week for 4 weeks) (11.6%) and/or a red blood cell transfusion (10.1%) based on the observed trial rates [29] .
Grade 3/4 rash was assumed to include one outpatient office visit and one tube of Cleocin-T gel [49, 52] . Treatment of grade 3/4 diarrhea included one office visit and one bottle of loperamide. Treatment for severe diarrhea included hospitalization (DRG 296) and the costs of inpatient physician visits. Leukopenia was assumed to be covered by the cost of treating neutropenia because of the high degree of overlap between conditions. Treatment costs for the remaining AEs included in the model consisted of one additional outpatient office visit per event.
The cost of PD was estimated from two studies which evaluated the cost of care for NSCLC patients in the 6 months before death using claims analysis data and chart reviews [27, 53] . The average monthly cost was multiplied by the time in PD.
The model included societal costs for patient time based on an assumed travel distance of 30 miles [54, 55] . All costs in the model were adjusted to 2006 values using the medical component of the consumer price index [56] .
Assessing Uncertainty
The uncertainty in the model was evaluated using one-way and multivariate probabilistic sensitivity analysis (PSA). One-way sensitivity analysis was performed by sequentially varying the estimates for each model parameter, while keeping the other [39, 40] Range estimates were likely values derived from confidence intervals or reasonable ranges as determined from published sources or expert opinion. BSC, best supportive care; CPT, current procedural terminology; DRG, diagnosis-related group; EGFR, epidermal growth factor receptor; IV, intravenous.
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parameters constant, within a range of likely values derived from confidence intervals or reasonable ranges as determined from published sources or expert opinion (see Table 1 ). In addition, a multivariate PSA was performed using second-order Monte Carlo simulation, in which the model inputs were drawn from probability distributions (normal distributions for costs, survival parameters, and utilities and beta distributions for probabilities) that represent the uncertainty in the estimate. The data were used to generate a cost-effectiveness acceptability frontier as well as the expected value of perfect information (EVPI) for the US population over a 5-year time frame [57] . The EVPI analysis estimates the average cost (including monetized QALYs) of wrong decisions because of uncertainty in the model parameters to estimate the upper bound value of perfect information [58] .
Results
The model yielded life expectancies for standard care with ERL, EGFR protein expression testing (IHC), and EGFR gene copy number testing (GC) of 0.79, 0.87, and 0.91 years, respectively. Adjusting for quality of life translated these values into QALY estimates of 0.44, 0.48, and 0.50, respectively. The cost estimates were $57,238, $63,512, and $66,447, respectively ( Table 2) . GC compared to ERL produced an incremental cost-effectiveness ratio (ICER) of $162,018/QALY, whereas IHC compared to ERL produced an ICER of $179,612. IHC was therefore dominated by extension by GC (i.e., GC is more cost-effective than IHC versus ERL).
The results of the one-way sensitivity analysis demonstrated that the effectiveness was most sensitive to uncertainty in the PFS, OS, and health state utility score on IV therapy estimates. The cost results were most sensitive to the overall and PFS estimates and the monthly cost in PD (Fig. 2) . The results of the multivariate PSA are provided as a cost-effectiveness frontier (Fig. 3 ). As this figure shows, ERL without testing was the optimal treatment strategy until the $150,000/QALY threshold, after which gene copy testing was optimal. The discounted EVPI at the $100,000/ QALY threshold in the USA over 5 years was $31.4 million, which represents the upper limit value of additional information at this threshold. Nevertheless, the EVPI varies with willingness to pay and as there is no agreed upon willingness-to-pay threshold in the USA, the EVPI may be as high as $92 to $100 million, corresponding with the $50,000 and $150,000/QALY thresholds, respectively (Table 3) .
We also undertook a threshold analysis in which we adjusted the benefit of ERL in the marker-positive groups by extending PFS and by extension OS. For the comparison of GC to ERL, we found that the time in PFS would need to extend from the base case estimate of 4.93 months to 9.24 months in high gene copy patients to achieve and ICER Յ$100,000/QALY. For IHC versus ERL, PFS would need to extend from 4.86 months in the base case to 7.12 months to achieve the same cost-effectiveness threshold.
Discussion
We evaluated two pharmacogenomic testing strategies for the treatment of advanced refractory NSCLC patients compared to standard care with ERL to estimate relative QALYs and treatment costs from the US societal perspective. Our results suggest there is the potential to improve quality-adjusted life expectancy by 3 weeks at an additional cost of $9200, which yields an ICER of $162,018/QALY for the comparison of testing (GC) versus no testing (ERL). The QALY improvement translates into a 1.4-month survival difference, which is within range of the treatment benefits observed for ERL and docetaxel over BSC in the key pivotal trials [3, 30] . In addition, the optimal testing option was found to be GC as it demonstrated better cost-effectiveness versus standard care with ERL than protein expression testing. The cost differences were relatively robust to sensitivity analysis, whereas the QALY differences were sensitive to changes in the efficacy estimates because of the uncertainty in these inputs. The uncertainty in the model is further reflected by the high EVPI, which represents the upper bound value of perfect information.
Overall, it appears as though pharmacogenomic testing using the gene copy number test in refractory advanced NSCLC has the potential to improve quality-adjusted survival over standard care with ERL by a clinically relevant margin. Although the ICERs are high, they are reflective of the cost of treatment in this setting. In essence, we would be paying for additional life expectancy at approximately the same rate we currently pay in this setting as reflected by the comparable cost per month of care for ERL, GC, and docetaxel ($6025, $6090, and $6330, respectively). If we are willing to use these treatments alone at their current value, it is reasonable to assume we would be willing to pay for the added cost of a pharmacogenomic test to optimize treatment selection and provide additional benefit.
There are a number of limitations in this analysis that warrant mention. The most significant limitation was the lack of data on marker status for the overall BR.21 population. The tested population is different from the overall study population both in terms of overall composition as well as the relative balance between the treated and untreated groups owing to the loss of randomization integrity. This difference is likely to be in part systematic as those with sufficient tumor tissue available for genomic analysis are more likely to have had prior surgical resection of their tumor which may indicate better prognosis at the time of diagnosis. The impact of this limitation is difficult to quantify; however, sensitivity ranges for these inputs were based on observed 95% confidence intervals and the best pharmacogenomic option (GC) maintained a 71% probability of improving QALYs over ERL in the PSA (data not shown).
Because this study is an indirect comparison, we do not have information as to the relative clinical efficacy, safety, and resource utilization for the interventions in the same population. As such, we assumed the same treatment benefit in terms of OS (i.e., OS in treated vs. BSC) for ERL and docetaxel. Although NICE has expressed some concerns with this assumption, it has face validity in that a recent ad hoc subgroup analysis comparing patients with similar levels of prior chemotherapy (less than 2) and performance status of 0 or 1 reported median survivals for ERL and docetaxel of 9.4 and 9.1 months, respectively [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . Ultimately, direct comparative trials are needed to determine whether there are statistically or clinically significant differences in survival and PFS between the treatment strategies.
Finally, the use of mean survival values derived from the published time to event survival curves using area under the curve calculations as opposed to estimates from individual patient level data is a limitation. Nevertheless, this method compared favorably against the published mean values for the overall treatment benefit (1.99 months vs. 2.06 months, respectively) [12, 35, 37] . Ideally, patient-level data from controlled trials would be used.
The results of our analysis are primarily hypothesis generating because of the reliance on retrospective analyses of data from randomized controlled trials. In this capacity, they provide a compelling argument for additional investigations of the clinical application of EGFR pharmacogenomic testing in advanced NSCLC. Our results suggest that using EGFR GC to select patients for treatment in second-line NSCLC is a promising tool for patient selection and warrants further high-level investigation, especially given the high EVPI.
Conclusion
The results of our study suggest that EGFR pharmacogenomic testing has the potential to improve quality-adjusted life expectancy in the treatment of refractory NSCLC by a clinically meaningful margin at a value commensurate with the approved therapies available in this setting. Given the high degree of uncertainty as to the relative effectiveness of these treatments, particularly in the genomic subgroups, the results of ongoing and future comparative clinical trials will provide valuable insight into the optimal treatment in second-line NSCLC and the potential of pharmacogenomic testing therein [59] .
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